Esmati Maryam, Monfaredi Fatemeh, Vakili Sadeghi Mohsen, Ranaii Mohammad, Ghorbani Hossein, Sedaghat Sadegh, Gholinia Hemmat
Student Research Committee, Babol University of Medical Sciences, Babol, Iran.
Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Caspian J Intern Med. 2024 Oct 19;16(1):141-150. doi: 10.22088/cjim.16.1.141. eCollection 2025 Winter.
Breast cancer management depends on molecular subtypes. The aim was to compare disease-free survival (DFS) among the different subgroups. Overall survival (OS) is a secondary endpoint.
This cross-sectional study was done on breast cancer women that were treated in our center, from 2009 to 2015. Breast cancer molecular subtypes were determined based on clinicopathological criteria recommended by St Gallen and include; luminal A, luminal B Her- 2-neu positive, luminal B Her-2-neu negative, Her-2 enriched and triple negative. Patients with metastasis at diagnosis or those without follow-up were excluded. Patients were followed-up from 12 to 132 months. Cox regression analysis was used for analogy of DFS and OS between the subgroups.
Out of three hundred patients, 221 were enrolled with median age of 47 years old (26 to 83). Luminal B, Her-2 negative was the most common subgroup with 83 patients (35.5%). Five and 10 years PFS were 95% and 81% for luminal A, were 95.5% and 92% for luminal B Her-2 positive, were 92% and 91% for luminal B Her-2 negative, were both 84% for triple negative and were 76% and 74% for Her-2 enriched subgroups, respectively. With multivariate analysis, the stage of tumor (HR=5.9 CI=1.06-32.69) and triple negative subgroup (HR=5.2 CI=1.33-20.31) were independent factors for recurrence.
Based on the results of this study, the triple-negative breast cancer and possibly Her-2 enriched subgroup have a shorter DFS than luminal breast cancers. Also, the stage of tumor is an independent factor for recurrence.
乳腺癌的治疗取决于分子亚型。目的是比较不同亚组的无病生存期（DFS）。总生存期（OS）是次要终点。
本横断面研究针对2009年至2015年在我们中心接受治疗的乳腺癌女性患者。根据圣加仑推荐的临床病理标准确定乳腺癌分子亚型，包括：腔面A型、腔面B型Her-2-neu阳性、腔面B型Her-2-neu阴性、Her-2富集型和三阴性。诊断时伴有转移或无随访的患者被排除。患者随访12至132个月。采用Cox回归分析比较各亚组之间的DFS和OS。
在300例患者中，221例被纳入研究，中位年龄47岁（26至83岁）。腔面B型Her-2阴性是最常见的亚组，有83例患者（35.5%）。腔面A型的5年和10年无进展生存期（PFS）分别为95%和81%，腔面B型Her-2阳性分别为95.5%和92%，腔面B型Her-2阴性分别为92%和91%，三阴性均为84%，Her-2富集型亚组分别为76%和74%。多因素分析显示，肿瘤分期（HR=5.9，CI=1.06-32.69）和三阴性亚组（HR=5.2，CI=1.33-20.31）是复发的独立因素。
基于本研究结果，三阴性乳腺癌以及可能的Her-2富集型亚组的DFS短于腔面型乳腺癌。此外，肿瘤分期是复发的独立因素。
